Initial Effects of the SB Natural Anticancer Drug on the Number of NK Cells, CD4+ and CD8+ T Lymphocytes in Human Peripheral Blood

Most anticancer drugs produce cytotoxicites in cancer cells, but also generate effects in normal cells that create undesirable side effects, especially for immune functioning cells which have already been suppressed by cancer invasion or biological effects. The SB natural anticancer drug is a root extract of the Pulsatilla koreana plant that has been used in Korea as an effective anticancer agent for more than 20 different malignant tumors without triggering significant adverse reactions. We investigated the effects of the SB anticancer drug on human immune cells in cancer patients. 24 consecutive patients, with histologically proven cancers, received SB drug treatments and 20 control patients did not receive SB administrations. Both groups were immunologically tested before and after their SB treatments for 14 days and then weekly for the 3rd, 4th, 5th and 6th weeks thereafter. The total number of white blood cells with differential counts including monocytes and lymphocytes were checked. Immunoassay and flow cytometry were used to analyse CD4 and CD8 T cell percentages, total cell counts with their ratios, as well as CD16/56 natural killer cell percentages and cell counts. Total white blood cell counts normalized within 10 days after the SB drug administrations. The total lymphocyte counts were slightly increased, but remained within normal parameters. CD4 and CD8 T cells, as well as CD 16/56 NK cell percentages, became normal within 10 days; their total cell counts were initially increased (26.3%, 45.2%, and 16.7%, respectively) and then became normal. The SB drug was found to be effective cytoapoptotically and was also effective for immune cell recovery in cancer patients in their initial period of the SB drug treatment. These were patients who had already had a bone marrow suppression by cancer invasion and/or prior chemotherapy.

[1]  T. Ganesan,et al.  Therapeutic antibodies against cancer stem cells: a promising approach , 2017, Cancer Immunology, Immunotherapy.

[2]  E. Kim,et al.  Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer , 2015 .

[3]  Kazumichi Yoshida,et al.  CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer , 2015, Cancer medicine.

[4]  Su Jin Lee,et al.  Reference Values for Peripheral Blood Lymphocyte Subsets in a Healthy Korean Population , 2014, Immune network.

[5]  Kab-Choong Kim,et al.  Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study , 2012, BMC Complementary and Alternative Medicine.

[6]  Andrew H. Beck,et al.  Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma , 2012, Proceedings of the National Academy of Sciences.

[7]  M. Schietzel,et al.  Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts. , 2007, Anticancer research.

[8]  Ji-Hyun Lee,et al.  Pulsatilla saponin D: The antitumor principle fromPulsatilla koreana , 2004, Archives of pharmacal research.

[9]  B. Ahn,et al.  Deoxypodophyllotoxin; the cytotoxic and antiangiogenic component from Pulsatilla koreana. , 2002, Planta medica.

[10]  E. Tokunaga,et al.  Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis , 2001, American Journal of Gastroenterology.

[11]  T. Kajiwara,et al.  Suppression of cellular immunity by surgical stress. , 2000, Surgery.

[12]  J. Marsh The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: a review. , 1976, Cancer research.

[13]  L. Lajtha Antineoplastic and Immunosuppressive Agents—Part 1 , 1975, British Journal of Cancer.

[14]  A. Sartorelli,et al.  Antineoplastic and Immunosuppressive Agents , 1975, Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology.